Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy-Reference-Cited by-同舟云学术

Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy

Published:2024-01 Issue: Volume: Page:
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Fletcher Sean A.,Pallauf Maximilian,Watts Emelia K.,Lombardo Kara A.,Campbell Jack A.,Rezaee Michael E.,Rouprêt Morgan,Boorjian Stephen A.,Potretzke Aaron M.,Roshandel M. Reza,Ploussard Guillaume,Djaladat Hooman,Ghoreifi Alireza,Mari Andrea,Campi Riccardo,Khene Zine-Eddine,Raman Jay D.,Kikuchi Eiji,Rink Michael,Abdollah Firas,Boormans Joost L.,Fujita Kazutoshi,D'Andrea David,Soria Francesco,Breda Alberto,Hoffman-Censits Jean,McConkey David J.,Shariat Shahrokh F.,Pradere Benjamin,Singla Nirmish

Publisher

Elsevier BV

Reference28 articles.

1. Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA/SUO guideline;Coleman;J Urol,2023

2. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update;Rouprêt;Eur Urol,2023

3. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy;Leow;Eur Urol,2021

4. Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs

5. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial;Birtle;Lancet,2020